Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP045071priorityCriticalpatent/ECSP045071A/en
Publication of ECSP045071ApublicationCriticalpatent/ECSP045071A/en
La invención se refiere a una combinación que comprende (a) un inhibidor de ciclooxigenasa-2 ("inhibidor de COX-2") y (b) un inhibidor de desacetilasa de histona ("HDAI") para uso simultáneo, concurrente, separado o secuencial, especialmente para utilizarse en el tratamiento de lesiones colon pre-malignas o un cáncer de colon u otras malignidades en un mamífero, particularmente un ser humano. La invención también se refiere a composiciones farmacéuticas que comprenden dicha combinación y a un método para tratar lesiones de colon pre-malignas (por ejemplo, pólipos) y cáncer de colon, así como otras malignidades, en un mamífero, particularmente un ser humano, con dicha combinación. La presente invención además también se refiere a un paquete o producto comercial que comprende dicha combinación.The invention relates to a combination comprising (a) a cyclooxygenase-2 inhibitor ("COX-2 inhibitor") and (b) a histone deacetylase inhibitor ("HDAI") for simultaneous, concurrent, separate or sequential, especially for use in the treatment of pre-malignant colon lesions or colon cancer or other malignancies in a mammal, particularly a human being. The invention also relates to pharmaceutical compositions comprising said combination and to a method for treating pre-malignant colon lesions (eg polyps) and colon cancer, as well as other malignancies, in a mammal, particularly a human being, with said combination. The present invention also further relates to a commercial package or product comprising said combination.
Use of a pharmaceutical composition containing cysteamine or cystamine in the preparation of a useful medicine for the treatment of non-alcoholic fatty liver disease (nafld) or non-alcoholic steatohepatitis (nash).
Isolated human monoclonal antibody that binds to the tissue factor pathway inhibitor (tfpi); pharmaceutical composition that includes it; use to treat acquired or genetic deficiencies of coagulation, or to shorten bleeding time.
USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
Compound derived from 2-arylamino-4-aminopyrimidines, c-alpha protein kinase inhibitors; pharmaceutical compositions containing them; and its use to treat or prevent diabetes, cancer, cardiovascular diseases and others.
PHARMACEUTICAL AGENT UNDERSTANDING 1) AN HER2 INHIBITOR THAT HAS A PIRROLOPIRIMIDINE OR PIRAZOLOPIRIMIDINE SKELETON AND 2) A HORMONAL OR ANTI-BANK THERAPEUTIC AGENT IN COMBINATION; AND USE FOR THE PREVENTION OR TREATMENT OF CANCER.